Investigation of ergoferonto suppress activity of respiratory syncytial virus in vitro
Viral infections of the lower respiratory tract are a major cause of morbidity and mortality among children, elderly and patients with immunodeficiency statements. Respiratory syncytial virus (RSV) - is the most common cause of bronchitis, bronchiolitis and pneumonia in infants. Up to 1 million deaths are annually registered worldwidedue to RSV infection. Most of the existing drugs against RSV are either not effective enough ortoo expensive. Ergoferonis a drug based on a mixture of polyclonal antibodies in release-active form against interferon gamma, CD4 receptor and histamine. Inthisstudyweexa minedtheabilityofErgoferonto suppress RSV infection in vitro. WeshowedthatpreincubationofErgoferonwithvirusleads to two-fold decrease in RSV titer. SucheffectofErgoferonisprobablycaused byalterations in viral proteins RSV-G and RSV-F, which are involved in entry of the virus into the cell.